MedPath

Phase II study of hypofractionated postoperative intensity-modulated radiotherapy for prostate cancer in adjuvant and salvage settings

Phase 2
Conditions
Prostate cancer
Registration Number
JPRN-UMIN000035287
Lead Sponsor
The University of Tokyo
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
Male
Target Recruitment
55
Inclusion Criteria

Not provided

Exclusion Criteria

a) patient refused to participate in this trial b) distant metastasis is recognized c) past history of irradiation to pelvis d) participation in another clinical trial which may affect this trial e) judged as inappropriate to participation by investigators

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The incidence of CTCAE grade 2-4 genitourinary and gastrointestinal toxicity during the initiation of radiotherapy and 90 days from the end of radiotherapy. Toxicities will be graded using CTCAE version 5.0. Biochemical recurrence-free survival
Secondary Outcome Measures
NameTimeMethod
Overall survival The incidence of toxicity during the initiation of radiotherapy and 90 days from the end of radiotherapy The incidence of toxicity during the follow-up period after 90 days from the end of radiotherapy Quality of life during the all follow-up period.
© Copyright 2025. All Rights Reserved by MedPath